Market Research Logo

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H2 2016’, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye)
    • The report reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Keratoconjunctivitis sicca (Dry Eye) therapeutics and enlists all their major and minor projects
    • The report assesses Keratoconjunctivitis sicca (Dry Eye) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Keratoconjunctivitis sicca (Dry Eye) Overview
    Therapeutics Development
    Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Overview
    Pipeline Products for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis
    Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Development by Companies
    Keratoconjunctivitis sicca (Dry Eye) - Therapeutics under Investigation by Universities/Institutes
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Keratoconjunctivitis sicca (Dry Eye) - Products under Development by Companies
    Keratoconjunctivitis sicca (Dry Eye) - Products under Investigation by Universities/Institutes
    Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development
    AB2 Bio Ltd.
    Allergan Plc
    Ascendia Pharmaceuticals LLC
    Chong Kun Dang Pharmaceutical Corp.
    Digna Biotech, S.L.
    Dompe Farmaceutici S.p.A.
    HanAll Biopharma Co., Ltd.
    Herantis Pharma Plc
    Huons Co., Ltd.
    InSite Vision Incorporated
    Kala Pharmaceuticals, Inc.
    Kissei Pharmaceutical Co., Ltd.
    KPI Therapeutics, Inc.
    Kukje Pharmaceutical Industry Co., Ltd.
    Laboratoires Thea S.A.
    Lee's Pharmaceutical Holdings Limited
    Lipicard Technologies Limited
    Merck & Co., Inc.
    Mimetogen Pharmaceuticals Inc.
    Mitotech S.A.
    Nanomerics Ltd
    Neuroptis Biotech
    Novaliq GmbH
    Ocular Therapeutix, Inc.
    Oculis ehf
    OncoNOx ApS
    Otsuka Holdings Co., Ltd.
    Parion Sciences, Inc.
    Quorum Innovations LLC
    RegeneRx Biopharmaceuticals, Inc.
    Rigel Pharmaceuticals, Inc.
    Samjin Pharmaceutical Co., Ltd.
    Santen Pharmaceutical Co., Ltd.
    Seikagaku Corporation
    Sucampo Pharmaceuticals, Inc.
    TearSolutions, LLC.
    TopiVert Ltd
    Xigen SA
    Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    AGN-223575 - Drug Profile
    AGN-232411 - Drug Profile
    Androgen Tears - Drug Profile
    AVA-3486 - Drug Profile
    AVX-012 - Drug Profile
    BRM-421 - Drug Profile
    cinhyaluronate sodium - Drug Profile
    Cis-Urocanic Acid - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine - Drug Profile
    cyclosporine SR - Drug Profile
    dexamethasone acetate SR - Drug Profile
    diclofenac sodium - Drug Profile
    diquafosol tetrasodium - Drug Profile
    disitertide - Drug Profile
    Drugs to Agonize FPR2 for Dry Eye - Drug Profile
    Elate Ocular - Drug Profile
    HL-036 - Drug Profile
    HU-007 - Drug Profile
    hyaluronate sodium - Drug Profile
    ISV-101 - Drug Profile
    K-089 - Drug Profile
    KeraKlear - Drug Profile
    KJ-14003 - Drug Profile
    KL-7016 - Drug Profile
    KPI-190 - Drug Profile
    Lacripep - Drug Profile
    LME-636 - Drug Profile
    loteprednol etabonate - Drug Profile
    LT-4002 - Drug Profile
    LT-4003 - Drug Profile
    NOP-3 - Drug Profile
    NOP-5 - Drug Profile
    Nov-03 - Drug Profile
    OC-301 - Drug Profile
    OX-1001 - Drug Profile
    ozagrel - Drug Profile
    P-321 - Drug Profile
    plastoquinone decyl triphenylphosphonium bromide - Drug Profile
    PPL-003 - Drug Profile
    Qi-204 - Drug Profile
    R-348 - Drug Profile
    rebamipide - Drug Profile
    Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
    RGN-259 - Drug Profile
    RP-101 - Drug Profile
    RU-101 - Drug Profile
    SA-001 - Drug Profile
    SJP-002 - Drug Profile
    Small Molecule to Agonize Glucocorticoid Receptor for Dry Eye - Drug Profile
    ST-266 - Drug Profile
    tadekinig alfa - Drug Profile
    tavilermide hydrochloride - Drug Profile
    TOP-1630 - Drug Profile
    XG-104 - Drug Profile
    ZK-003 - Drug Profile
    zucapsaicin - Drug Profile
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects
    Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products
    Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones
    Featured News & Press Releases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016
    Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Development by Companies, H2 2016 (Contd..2)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Products under Development by Companies, H2 2016 (Contd..3)
    Products under Investigation by Universities/Institutes, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by AB2 Bio Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Digna Biotech, S.L., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Herantis Pharma Plc, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by InSite Vision Incorporated, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by KPI Therapeutics, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea S.A., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Lipicard Technologies Limited, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co., Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech S.A., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Neuroptis Biotech, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Parion Sciences, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharmaceutical Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corporation, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions, LLC., H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..1), H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..2), H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..3), H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..4), H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects (Contd..5), H2 2016
    Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H2 2016
    Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Top 10 Routes of Administration, H2 2016
    Number of Products by Stage and Top 10 Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report